

Sven Mahner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3460568/sven-mahner-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

222
papers

3,638
citations

23
h-index

55
g-index

248
ext. papers

4,862
ext. citations

4.5
avg, IF

4.93
L-index

#	Paper	IF	Citations
222	Effects of matcha tea extract on cell viability and peroxisome proliferator-activated receptor α expression on T47D breast cancer cells.. <i>Archives of Gynecology and Obstetrics</i> , 2022 , 1	2.5	1
221	AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin.. <i>Scientific Reports</i> , 2022 , 12, 1862	4.9	1
220	A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.. <i>International Journal of Gynecological Cancer</i> , 2022 ,	3.5	1
219	Seasonal dynamic of cholecalciferol (D3) and anti-Muellerian hormone (AMH) with impact on ovarian response and IVF/ICSI.. <i>Archives of Gynecology and Obstetrics</i> , 2022 , 1	2.5	1
218	Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report.. <i>Journal of Medical Case Reports</i> , 2022 , 16, 119	1.2	0
217	Galectin-8 and -9 as prognostic factors for cervical cancer.. <i>Archives of Gynecology and Obstetrics</i> , 2022 , 1	2.5	0
216	Overexpression of galectin-4 in placentas of women with gestational diabetes.. <i>Journal of Reproductive Immunology</i> , 2022 , 151, 103629	4.2	1
215	Gal-2 Increases H3K4me3 and H3K9ac in Trophoblasts and Preeclampsia. <i>Biomolecules</i> , 2022 , 12, 707	5.9	0
214	Factors Influencing the In Vitro Maturation (IVM) of Human Oocyte.. <i>Biomedicines</i> , 2021 , 9,	4.8	1
213	Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	1
212	Adjuvant radiotherapy and local recurrence in vulvar cancer - a subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2021 ,	4.9	1
211	Epigenetic changes occur in placentas of spontaneous and recurrent miscarriages.. <i>Journal of Reproductive Immunology</i> , 2021 , 149, 103466	4.2	0
210	The role of Interleukin-18 in recurrent early pregnancy loss. <i>Journal of Reproductive Immunology</i> , 2021 , 148, 103432	4.2	0
209	The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro. <i>Cells</i> , 2021 , 10,	7.9	5
208	Integrin $\alpha 2 \beta 1$ Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer. <i>Biomedicines</i> , 2021 , 9,	4.8	2
207	Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study. <i>Annals of Surgical Oncology</i> , 2021 , 28, 6696-6704	3.1	1
206	Combined COX-2/PPAR γ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients. <i>Diagnostics</i> , 2021 , 11,	3.8	1

205	A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
204	Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). <i>Breast Cancer Research</i> , 2021 , 23, 45	8.3	0
203	Interleukin-1 beta is significantly upregulated in the decidua of spontaneous and recurrent miscarriage placentas. <i>Journal of Reproductive Immunology</i> , 2021 , 144, 103283	4.2	6
202	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium. <i>Cancers</i> , 2021 , 13,	6.6	6
201	Expression of the Carbohydrate Lewis Antigen, Sialyl Lewis A, Sialyl Lewis X, Lewis X, and Lewis Y in the Placental Villi of Patients With Unexplained Miscarriages. <i>Frontiers in Immunology</i> , 2021 , 12, 679424	8.4	2
200	Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2021 , 161, 442-448	4.9	0
199	The decidual expression of Interleukin-7 is upregulated in early pregnancy loss. <i>American Journal of Reproductive Immunology</i> , 2021 , 86, e13437	3.8	1
198	Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR-17/BOGOT, GINECO-OV118, ENGOT-Ov-15, NCT01462896). <i>Journal of Clinical Oncology</i> , 2021 , 39, 1500-1509	2.2	7
197	Well-being during COVID-19 pandemic: A comparison of individuals with minoritized sexual and gender identities and cis-heterosexual individuals. <i>PLoS ONE</i> , 2021 , 16, e0252356	3.7	9
196	p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 595.e1-595.e11	6.4	7
195	Epigenetic modification via H3K4me3 and H3K9ac in human placenta is reduced in preeclampsia. <i>Journal of Reproductive Immunology</i> , 2021 , 145, 103287	4.2	4
194	Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
193	Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 217-230	2.5	2
192	NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 1331-1345	2.5	3
191	Late Presentation at Primary Diagnosis of Breast Cancer: PatientsSPersonality Characteristics and Attitudes. <i>Breast Care</i> , 2021 , 16, 343-349	2.4	
190	Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. <i>Translational Oncology</i> , 2021 , 14, 100910	4.9	3
189	G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021 , 12, 564002	5.7	4
188	First Evidence for a Role of Siglec-8 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2

187	Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
186	Pregnancy Zone Protein (PZP) is significantly upregulated in the decidua of recurrent and spontaneous miscarriage and negatively correlated to Glycodelin A (GdA). <i>Journal of Reproductive Immunology</i> , 2021 , 143, 103267	4.2	2
185	Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. <i>Journal of Ovarian Research</i> , 2021 , 14, 89	5.5	
184	Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. <i>Cancers</i> , 2021 , 13,	6.6	1
183	Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
182	Comparison of Histone H3K4me3 between IVF and ICSI Technologies and between Boy and Girl Offspring. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
181	Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 713026	5.3	
180	Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gynecologic center in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1	2.5	0
179	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. <i>Journal of Gynecologic Oncology</i> , 2021 , 32, e37	4	2
178	tRNA-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression.. <i>Cancers</i> , 2021 , 14,	6.6	2
177	Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics. <i>Psycho-Oncology</i> , 2021 ,	3.9	1
176	The role of resveratrol, Sirtuin1 and RXR α as prognostic markers in ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1	2.5	
175	Effects of intralipid infusions on anti-trophoblast antibody (ATAb)-activities in patients with recurrent pregnancy loss: An observational report.. <i>American Journal of Reproductive Immunology</i> , 2021 , e13506	3.8	
174	LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
173	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. <i>Breast Cancer Research</i> , 2020 , 22, 111	8.3	6
172	M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis. <i>Cells</i> , 2020 , 9,	7.9	10
171	Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2189-2203	4.9	4
170	Expression of H3K4me3 and H3K9ac in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2017-2027	4.9	3

169	Spliceosome protein EFTUD2 is upregulated in the trophoblast of spontaneous miscarriage and hydatidiform mole. <i>Journal of Reproductive Immunology</i> , 2020 , 140, 103149	4.2	1
168	Cell Type- and Sex-Specific Dysregulation of Thyroid Hormone Receptors in Placentas in Gestational Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
167	Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 1923-1932	4.9	3
166	EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
165	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423	12.9	21
164	Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 1847-1855	4.9	3
163	H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1 α ,25(OH) $_2$ D $_3$) in Ovarian Cancer Biology. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
162	Cytoplasmic VDR expression as an independent risk factor for ovarian cancer. <i>Histochemistry and Cell Biology</i> , 2020 , 154, 421-429	2.4	2
161	Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. <i>Histochemistry and Cell Biology</i> , 2020 , 154, 189-195	2.4	2
160	MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
159	miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020 , 147, 3560-3573	7.5	4
158	PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 569-577	4.9	6
157	Cytoplasmic PPAR α is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. <i>Journal of Translational Medicine</i> , 2020 , 18, 94	8.5	7
156	The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases. <i>Scientific Reports</i> , 2020 , 10, 1154	4.9	4
155	Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β Are Inversely Associated with Survival in Primary Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
154	Sex-specific epigenetic gene activation profiles are differentially modulated in human placentas affected by intrauterine growth restriction. <i>Journal of Reproductive Immunology</i> , 2020 , 139, 103124	4.2	2
153	Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. <i>Archives of Gynecology and Obstetrics</i> , 2020 , 301, 1267-1274	2.5	2
152	High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	8

151	The Distinct Roles of Transcriptional Factor KLF11 in Normal Cell Growth Regulation and Cancer as a Mediator of TGF- β Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
150	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6068-6068	2.2	4
149	Evaluation of treatment patterns and prognosis in correlation with age in patients with vulvar cancer: A subset analysis of the AGO-CaRE-1 study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6090-6090	2.2	
148	Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 1221-1228	2	1
147	Metastatic Breast Cancer: Is There a Differential Therapy Efficacy between Visceral and Non-Visceral Metastatic Breast Cancer?. <i>Breast Care</i> , 2020 , 15, 527-533	2.4	
146	Errestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation. <i>Frontiers in Endocrinology</i> , 2020 , 11, 554733	5.7	9
145	Expression of trophoblast derived prostaglandin E2 receptor 2 (EP2) is reduced in patients with recurrent miscarriage and EP2 regulates cell proliferation and expression of inflammatory cytokines. <i>Journal of Reproductive Immunology</i> , 2020 , 142, 103210	4.2	2
144	Early Life Oxidative Stress and Long-Lasting Cardiovascular Effects on Offspring Conceived by Assisted Reproductive Technologies: A Review. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
143	Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2559-2574	4.9	1
142	Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
141	Sex Specific Expression of Interleukin 7, 8 and 15 in Placentas of Women with Gestational Diabetes. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
140	LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1548-1553	3.5	5
139	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
138	L-Dopa-Decarboxylase (DDC) Is a Positive Prognosticator for Breast Cancer Patients and Epinephrine Regulates Breast Cancer Cell (MCF7 and T47D) Growth In Vitro According to Their Different Expression of. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
137	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020 , 41, 442-451	4.6	4
136	EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients. <i>Breast Care</i> , 2020 , 15, 171-177	2.4	3
135	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <i>The</i> , 2020 , 21, 699-709	21.7	62
134	Oropharyngeal HPV Detection Techniques in HPV-associated Head and Neck Cancer Patients. <i>Anticancer Research</i> , 2020 , 40, 2117-2123	2.3	3

133	Placental Galectin-2 Expression in Gestational Diabetes: A Systematic, Histological Analysis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
132	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 1327-1331	3.5	49
131	Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. <i>Cancers</i> , 2019 , 11,	6.6	11
130	EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2519-2527	4.9	5
129	EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells. <i>OncoTargets and Therapy</i> , 2019 , 12, 6053-6068	4.4	10
128	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019 , 9, 832	5.3	7
127	Prognostic relevance of RIP140 and ER α expression in unifocal versus multifocal breast cancers: a preliminary report. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
126	Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	8
125	Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. <i>Gynecologic Oncology</i> , 2019 , 154, 565-570	4.9	9
124	Glucocorticoid receptors α and β are modulated sex specifically in human placentas of intrauterine growth restriction (IUGR). <i>Archives of Gynecology and Obstetrics</i> , 2019 , 300, 323-335	2.5	7
123	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019 , 17, 537-560	6.8	11
122	A randomized trial comparing limited-excision conisation to Large Loop Excision of the Transformation Zone (LLETZ) in cervical dysplasia patients. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e42	4	6
121	Anti α -enolase antibody is a novel autoimmune biomarker for unexplained recurrent miscarriages. <i>EBioMedicine</i> , 2019 , 41, 610-622	8.8	10
120	The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
119	Liver rupture in a 28-year-old primigravida with superimposed pre-eclampsia and hemolysis, elevated liver enzyme levels, and low platelet count syndrome. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019 , 45, 1066-1070	1.9	3
118	Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. <i>Breast Cancer: Targets and Therapy</i> , 2019 , 11, 87-97	3.9	9
117	Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study. <i>Strahlentherapie Und Onkologie</i> , 2019 , 195, 289-296	4.3	4
116	Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019 , 154, 571-576	4.9	9

115	The Formation and Therapeutic Update of Tumor-Associated Macrophages in Cervical Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	11
114	Extracapsular Lymph Node Involvement in Ovarian Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	3
113	Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. <i>Cancer Management and Research</i> , 2019 , 11, 7673-7684	3.6	8
112	Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019 , 153, 286-291	4.9	15
111	Hormone Receptor Expression in Multicentric/Multifocal versus Unifocal Breast Cancer: Especially the VDR Determines the Outcome Related to Focality. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	7
110	Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients. <i>Cancers</i> , 2019 , 11,	6.6	8
109	The role of EP3-receptor expression in cervical dysplasia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 313-319	4.9	3
108	Delayed interval delivery in multiple gestations: the Munich experience. <i>Archives of Gynecology and Obstetrics</i> , 2019 , 299, 339-344	2.5	3
107	Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	4
106	Involvement of ILR4 and TLR4 in miscarriages. <i>Journal of Reproductive Immunology</i> , 2019 , 131, 36-43	4.2	8
105	Efficacy and safety of niraparib as maintenance treatment in older patients (≥70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. <i>Gynecologic Oncology</i> , 2019 , 152, 560-567	4.9	19
104	Sexual activity and quality of life in patients after treatment for breast and ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2019 , 299, 191-201	2.5	15
103	Glucocorticoid receptor in cervical cancer: an immunohistochemical analysis. <i>Archives of Gynecology and Obstetrics</i> , 2019 , 299, 203-209	2.5	6
102	MR Pelvimetry for Breech Presentation at Term- Interobserver Reliability, Incidental Findings and Reference Values. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2019 , 191, 424-432	2.3	
101	Effects of green tea, matcha tea and their components epigallocatechin gallate and quercetin on MCF-7 and MDA-MB-231 breast carcinoma cells. <i>Oncology Reports</i> , 2019 , 41, 387-396	3.5	28
100	Peri-operative oral immunonutrition in malnourished ovarian cancer patients assessed by the nutritional risk screening. <i>Archives of Gynecology and Obstetrics</i> , 2018 , 297, 1533-1538	2.5	5
99	No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas. <i>Journal of Neurology</i> , 2018 , 265, 431-432	5.5	1
98	Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases. <i>Radiation Oncology</i> , 2018 , 13, 25	4.2	8

97	Dopamine synthesis and dopamine receptor expression are disturbed in recurrent miscarriages. <i>Endocrine Connections</i> , 2018 , 7, 727-738	3.5	3
96	Prostaglandin E receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses. <i>Endocrine Connections</i> , 2018 , 7, 749-761	3.5	11
95	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , 2018 , 18, 175-183	3	11
94	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. <i>Breast Care</i> , 2018 , 13, 126-130	2.4	1
93	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018 , 149, 371-380	4.9	9
92	Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial. <i>Clinical Breast Cancer</i> , 2018 , 18, e1103-e1110	3	
91	PPAR α Expression Is Diminished in Macrophages of Recurrent Miscarriage Placentas. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
90	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. <i>BMC Cancer</i> , 2018 , 18, 431	4.8	13
89	Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients. <i>BMC Cancer</i> , 2018 , 18, 141	4.8	15
88	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 1247-1258	21.7	49
87	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5567-5567	2.2	4
86	Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients. <i>Oncotarget</i> , 2018 , 9, 982-994	3.3	12
85	Interaction of ER α and NRF2 Impacts Survival in Ovarian Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2018 , 20,	6.3	17
84	Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 249-256	4.9	12
83	Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium. <i>Histochemistry and Cell Biology</i> , 2018 , 149, 153-160	2.4	7
82	Histone H3 lysine 9 acetylation is downregulated in GDM Placentas and Calcitriol supplementation enhanced this effect. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	8
81	Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	15
80	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018 , 9, 842	5.6	3

79	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018 , 151, 61-68	4.9	22
78	Prognostic impact of residual disease in simultaneous additional excision specimens after one-step breast conserving therapy with negative final margin status in primary breast cancer. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1318-1323	3.6	6
77	Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results. <i>Brachytherapy</i> , 2018 , 17, 775-781	2.4	26
76	Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2017 , 17, 279-285	3	8
75	MR pelvimetry: prognosis for successful vaginal delivery in patients with suspected fetopelvic disproportion or breech presentation at term. <i>Archives of Gynecology and Obstetrics</i> , 2017 , 295, 351-359	2.5	8
74	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. <i>Journal of Clinical Oncology</i> , 2017 , 35, 587-590	2.2	30
73	Short interval between two Pap smears: effect on the result of the second smear? A prospective randomized trial. <i>Archives of Gynecology and Obstetrics</i> , 2017 , 295, 1427-1433	2.5	3
72	Prevalence of human papillomavirus infection of the anal canal in women: A prospective analysis of high-risk populations. <i>Oncology Letters</i> , 2017 , 13, 2495-2501	2.6	11
71	Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1314-1321	3.1	23
70	Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only. <i>Oncology Letters</i> , 2017 , 14, 3302-3308	2.6	7
69	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017 , 8, 106415-106428	3.3	25
68	RE: Post-traumatic Stress as the Primary Cause for Cognitive Decline-Not the Whole Story, and Perhaps No Story at All. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	1
67	LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells. <i>Molecular Oncology</i> , 2017 , 11, 1508-1526	7.9	14
66	Expression of Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16 in cervical dysplasia. <i>Future Oncology</i> , 2017 , 13, 145-157	3.6	6
65	Induction of DNA damage and apoptosis in human leukemia cells by efavirenz. <i>Oncology Reports</i> , 2017 , 37, 617-621	3.5	8
64	Role of Placental VDR Expression and Function in Common Late Pregnancy Disorders. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	31
63	The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	14
62	Vitamin D and VDR in Gynecological Cancers-A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	37

61	TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33 / AGO-OVAR OP7).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS5602-TPS5602	2.2	8
60	Loss of promotor hypermethylation in recurrent high-grade ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 83063-83074	3.9	14
59	The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7). <i>Anticancer Research</i> , 2017 , 37, 95-102	2.3	4
58	LKB1 and its importance for survival in EpCAM negative circulating tumor cells (CTC) in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23061-e23061	2.2	
57	Patterns of distant metastases in vulvar cancer. <i>Gynecologic Oncology</i> , 2016 , 142, 427-34	4.9	36
56	Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. <i>European Journal of Cancer</i> , 2016 , 69, 180-188	7.5	47
55	In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines. <i>International Journal of Molecular Medicine</i> , 2016 , 38, 1296-302	4.4	6
54	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , 2016 , 17, 643	4.5	11
53	Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review). <i>Oncology Reports</i> , 2016 , 35, 1905-15	3.5	24
52	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. <i>Tumor Biology</i> , 2016 , 37, 3009-16	2.9	21
51	Sexual activity and function after surgical treatment in patients with (pre)invasive vulvar lesions. <i>Supportive Care in Cancer</i> , 2016 , 24, 419-428	3.9	12
50	Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e17029-e17029	2.2	1
49	Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer. <i>PLoS ONE</i> , 2016 , 11, e0165705	3.7	12
48	Prognosis after local recurrence in vulvar cancer: A subset analysis of the AGO-CaRE-1 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5595-5595	2.2	
47	The course of vulvar cancer: The utility of multistate models in the AGO-CaRE-1 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5596-5596	2.2	
46	Placental Expression Patterns of Galectin-1, Galectin-2, Galectin-3 and Galectin-13 in Cases of Intrauterine Growth Restriction (IUGR). <i>International Journal of Molecular Sciences</i> , 2016 , 17, 523	6.3	20
45	Local Resection of Primary Tumor in Upfront Stage IV Breast Cancer. <i>Breast Care</i> , 2016 , 11, 411-417	2.4	3
44	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 2154-2164	59.2	1259

43	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016 , 36, 1015-22	2.3	4
42	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. <i>British Journal of Cancer</i> , 2015 , 113, 1358-66	8.7	91
41	Fetal gender specific expression of tandem-repeat galectins in placental tissue from normally progressed human pregnancies and intrauterine growth restriction (IUGR). <i>Placenta</i> , 2015 , 36, 1352-61	3.4	11
40	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology</i> , 2015 , 16, 87-97	21.7	405
39	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2015 , 5, 211	5.3	15
38	Systemic treatment of vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 629-37	3.5	25
37	Cadherin-11 mRNA and protein expression in ovarian tumors of different malignancy: No evidence of oncogenic or tumor-suppressive function. <i>Molecular and Clinical Oncology</i> , 2015 , 3, 1067-1072	1.6	3
36	Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	117
35	Efficacy and safety of chemotherapy (CT) + pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5504-5504	2.2	3
34	A systematic model specification procedure for an illness-death model without recovery. <i>PLoS ONE</i> , 2015 , 10, e0123489	3.7	11
33	Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5578-5578	2.2	
32	The risk of contralateral non sentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16600-e16600	2.2	1
31	Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5552-5552	2.2	
30	Analysis of heat shock protein HSP27 secretion in an ovarian cancer cell model and detection of cell-free HSP27 in patient blood serum sample.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16570-e16570	2.2	
29	Clinical management of epithelial ovarian cancer during pregnancy. <i>European Journal of Cancer</i> , 2014 , 50, 963-71	7.5	28
28	Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2014 , 25, 221-8	4	23
27	HIF1 α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium. <i>OncoTargets and Therapy</i> , 2014 , 7, 1563-9	4.4	17
26	Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5565-5565	2.2	1

25	A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5625-TPS5625	2.2	4
24	Surgical staging and its prognostic impact on patients with borderline ovarian tumors (BOT): A subanalysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5562-5562	2.2	
23	Resection margin and locoregional control in vulvar cancer: A subset analysis of the AGO CARE-1 multicenter study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5608-5608	2.2	
22	Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5552-5552	2.2	
21	Adjuvant therapy in node-positive vulvar cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 839-44	3.5	5
20	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013 , 128, 15-21	4.9	86
19	Towards individualised treatment in ovarian cancer. <i>Lancet Oncology, The</i> , 2013 , 14, 101-2	21.7	2
18	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. <i>Epigenetics</i> , 2013 , 8, 1226-35	5.7	16
17	Outcome parameters in node-negative vulvar cancer: A subset analysis of the AGO Care 1 study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5531-5531	2.2	
16	Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5593-5593	2.2	
15	Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16535-e16535	2.2	
14	Does alopecia predict response to chemotherapy and prognosis in patients with advanced ovarian cancer? A meta-analysis of prospective randomized phase III trials with 5,114 patients of the AGO meta data base.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5553-5553	2.2	
13	Serum mass spectrometry analysis in primary ovarian cancer (OC) treated with surgery and adjuvant chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5575-5575	2.2	
12	A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1413-9	4.9	12
11	Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5005-5005	2.2	2
10	Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5007-5007	2.2	5
9	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5031-5031	2.2	3
8	How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5087-5087	2.2	

7	Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5034-5034	2.2	
6	Treatment reality in elderly patients with advanced ovarian cancer: A prospective analysis of the OVCAD consortium.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5058-5058	2.2	
5	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5071-5071	2.2	1
4	Recurrent ovarian cancer and management of elderly patients: Results of a prospective trial of treosulfan focusing on patient's preference and clinical outcome (NOGGO-Preference-Study).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15520-e15520	2.2	
3	Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2011 , 29, 242-8	2.2	79
2	TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. <i>BMC Cancer</i> , 2010 , 10, 139	4.8	32
1	Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction. <i>Anticancer Research</i> , 2009 , 29, 2817-21	2.3	4